Skip to main content
Ingredients/Compound/Astragaloside IV (TA-65 type)

Astragaloside IV (TA-65 type).

Telomerase activator. Longevity compound from astragalus. Supports immune cell activity and may enhance resistance to stress

Extensively studiedResearch depth5 to 50mgDaily amount4,547Studies read

Reviewed March 2026

AICompound
Astragaloside IV (TA-65 type)IngredientMD
Category
Compound

Also filed under
LongevityImmuneTelomeres

What Astragaloside IV (TA-65 type) is, and what it does.

Does it work
Decent traditional medicine backing but limited modern clinical trials on isolated astragalosides
How much to take
10-50mg astragalosides daily (equivalent to 2-6g whole root extract)
Time to feel it
Nobody has mapped a time course for isolated astragalosides in people. Traditional use and the extract studies run in months rather than days.
The first dose
Nothing noticeable. This is a slow-building supplement.
With regular use
May notice fewer sick days or faster recovery. Subtle but potentially meaningful.
How well tolerated
Generally well tolerated at the amounts used. It is an immune-active saponin, so anyone on medication that damps immune activity should run it past a clinician first.
How it feels
Most people feel nothing directly. The benefit shows up as overall resilience.
The overlooked benefit
Gut bacteria strip the sugars off before absorption, so what circulates is largely cycloastragenol. Your microbiome does part of the manufacturing.

5 to 50mg a day is where Astragaloside IV (TA-65 type) works.

How much to take a dayMedium confidence
5 to 50mg
Daily maintenanceThe everyday amount, and where most daily supplements sit. This is the one you take month after month.
6,000mgClinical territory. Trials run high on purpose, for a set number of weeks, against one measured outcome. Impressive to hit, and not what a daily product is for.
Above 10,000mgPast what the research covers. More capsules rather than more effect.
MORE EFFECT ↑02,000mg6,000mg plateauDAILY DOSE →
The shaded band is where the dosing trials landed.

Source: Liu et al. 2017 Am J Chin Med review; Chinese Pharmacopoeia monograph.

The proof, claim by claim.

These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.

Extensively studied.

Based on 8 human trials with 50% consistency.

  • Telomerase enzyme activity in cultured cellsIn vitro study
  • Immune cell profile in older adultsRandomised trial
  • Heart and vessel markersAnimal study
  • Resistance to physical stressAnimal study
  • Traditional use of astragalus root as a tonicNarrative review
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI4,547 studies readLabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI4,547 studies readLabs test. IngredientMD verifies.

Questions people ask about Astragaloside IV (TA-65 type).

When should I take it?
Timing matters less than consistency. Pick a time that works for you and take it daily.
Can I take it with other supplements?
Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
Any side effects to watch for?
Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Pairs well with12 on file

Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.

Astragaloside IV (TA-65 type) + astragalusSource relationship: astragalosides are the marker saponins of Astragalus membranaceus root.

An astragaloside preparation is a concentrate of compounds that occur naturally in the whole root. A whole-root product delivers the same saponins alongside polysaccharides and flavonoids at far lower saponin concentration. Anyone comparing the two is comparing a standardised isolate with a whole extract, not two different ingredients.

Astragaloside IV (TA-65 type) + mct-oilEstablished solubility behaviour of triterpenoid saponins and their aglycones.

Astragaloside IV is a large, poorly water-soluble saponin and its aglycone cycloastragenol is more lipophilic still. Lipid vehicles are used to disperse compounds with that profile and to keep them in solution through the gut lumen. The rationale is delivery; no pairing trial is being cited.

Astragaloside IV (TA-65 type) + ginseng-panaxShared chemistry: both supply triterpenoid saponins that undergo gut microbial deglycosylation before absorption.

Ginsenosides and astragalosides are both glycosylated triterpenes that intestinal bacteria strip of sugars to release more absorbable aglycones. That shared activation route means gut microbial composition influences exposure to either. The two are also combined in traditional preparations. Read the pairing as chemical and traditional rather than clinically measured.

Astragaloside IV (TA-65 type) + dang-guiClassical formulation pairing in which Astragalus root and Angelica sinensis root are combined at a fixed ratio.

The Astragalus and Angelica pairing is one of the most documented two-herb combinations in the traditional literature, used as a single unit rather than two separate additions. Astragalosides are the saponin markers on the Astragalus side of that pair. The pairing is documented as practice; it is not a statement about a measured effect.

Astragaloside IV (TA-65 type) + licorice-rootTraditional formulation practice plus shared triterpenoid saponin chemistry.

Licorice contributes glycyrrhizin, another triterpene glycoside, and it appears alongside Astragalus in many classical formulas as a harmonising component. Glycyrrhizin also has surfactant behaviour that can help disperse other saponins. Licorice carries its own blood pressure and potassium considerations at sustained intake, which is the practical limit on the pairing.

Astragaloside IV (TA-65 type) + cordycepsCommon combination in adaptogen-style formulas; the shared basis is formulation convention rather than a measured interaction.

Cordyceps and Astragalus preparations are routinely blended in tonic formulations. No combination trial is cited here and none is implied. The pairing is formulation convention.

Astragaloside IV (TA-65 type) + reishiFormulation convention in traditional tonic blends.

Reishi contributes its own triterpenes and beta-glucans and is commonly blended with Astragalus material. The two contribute chemically distinct fractions. This row records the convention, not an effect.

Astragaloside IV (TA-65 type) + rhodiola-roseaCommon co-formulation in adaptogen products.

Rhodiola supplies rosavins and salidroside, a chemically unrelated set of compounds from the astragalosides. They are combined because product categories group them, not because an interaction has been measured. Read it as formulation practice.

Astragaloside IV (TA-65 type) + resveratrolOverlapping interest in cellular ageing markers; mechanistic and preclinical only.

Both compounds are studied against cell-level ageing markers, resveratrol through sirtuin-linked signalling and cycloastragenol through telomerase activity in cell systems. These are laboratory markers, not clinical outcomes, and no combination trial in people is cited. The row exists to record the shared research context.

Astragaloside IV (TA-65 type) + pterostilbeneSame shared-marker research context as resveratrol, with a methylated stilbene.

Pterostilbene is the dimethylated analogue of resveratrol and appears in the same cellular-ageing product category as cycloastragenol preparations. Any link is at the level of laboratory markers. No human combination data is claimed.

Astragaloside IV (TA-65 type) + nicotinamide-riboside-nrProduct-category pairing in cellular ageing formulas; mechanistic rationale only.

NAD precursors and telomere-focused saponins are marketed into the same category and act on entirely different biochemistry, one on nicotinamide nucleotide pools and the other on cell-level telomerase signalling. There is no measured interaction between them being cited. Read the pairing as categorical.

Astragaloside IV (TA-65 type) + vitamin-cEstablished antioxidant biochemistry as general context, not a specific measured pairing.

Ascorbate is the water-phase reducing agent that supports several antioxidant systems in the cell. Astragaloside preparations are studied against oxidative stress markers in preclinical models. The two are combined on that general rationale, which is weak grounding and is labelled accordingly.

Who should be cautious

Nothing specific on file for Astragaloside IV (TA-65 type). Match the label to the daily amount above, and tell your doctor what you take.

Not medical advice. Show the label to your pharmacist.

What Astragaloside IV (TA-65 type) actually does.

Established

Astragaloside IV is a cycloartane-type triterpenoid saponin from the root of Astragalus membranaceus, built on a cycloastragenol core carrying xylose and glucose sugars.

Established

Removing those sugars, by acid or enzymatic hydrolysis or by gut bacteria, yields the aglycone cycloastragenol, which is the compound in TA-65 type preparations.

Established

Saponins including astragalosides are surface-active molecules, which is why they foam in water and why they interact with lipid membranes in laboratory assays.

Established

Astragaloside content in a root extract varies with the plant's age, growing region and the solvent used, so a preparation is defined by its assayed saponin percentage rather than by the plant name alone.

Grown, 6 steps on record

Where Astragaloside IV (TA-65 type) comes from.

It starts as a dried root, usually several years old. Alcohol and water pull the saponins out, then resin columns and chromatography strip away everything else until what is left is mostly the one compound. For the cycloastragenol version, a further step snips the sugars off that molecule. The finished powder is measured by lab assay so the label number means something.

Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.

Starts as
Astragalus membranaceus root

Dried roots, usually four years or older, from cultivated Astragalus membranaceus or its variety mongholicus; saponin content varies with age, region and harvest season.

Extracted by
Hydroalcoholic extraction

Milled root is extracted with aqueous ethanol, which pulls the saponin fraction while leaving much of the polysaccharide behind.

Purified by
Resin and chromatographic clean-up

The crude extract is passed over macroporous resin and then chromatography to concentrate astragaloside IV away from flavonoids, sugars and other saponins.

Converted by
Hydrolysis to the aglycone

For cycloastragenol material, the purified glycoside is hydrolysed enzymatically or under acid to remove the xylose and glucose units, then re-purified.

Standardised to
HPLC assay to a stated percentage

The concentrate is assayed by HPLC against a reference standard and blended with a carrier to hit the declared astragaloside IV or cycloastragenol content.

Ends up as
Powder or capsule

Finished material is a fine powder, often carried on maltodextrin or a lipid excipient, and filled into capsules at milligram-scale doses.

Getting Astragaloside IV (TA-65 type) from food.

The whole-food sources on file. A supplement closes the gap, it does not replace dinner.

Astragalus membranaceus root

A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.

The forms it comes in.

Aglycone concentrateThe sugar-free core produced by hydrolysing astragaloside IV, more lipophilic than the parent glycoside.Fits Preparations built around the aglycone, including TA-65 type products.Trade-off It requires a hydrolysis and purification step, so material cost and assay verification carry more weight than with a plain root extract.
Full-spectrum root extractA water or hydroalcoholic extract carrying polysaccharides and flavonoids alongside a low percentage of saponins.Fits Traditional-style preparations where the polysaccharide fraction is part of the intent.Trade-off Saponin content is low and variable, so a stated astragaloside dose usually is not achievable from this form.
Solubilised delivery formThe saponin dispersed in a lipid vehicle or complexed with a cyclodextrin to keep it in solution through the gut.Fits Formulas addressing the poor aqueous behaviour of the parent glycoside.Trade-off The carrier adds excipient load, and the delivery rationale rests on physical chemistry rather than on comparative human data.Active and formulation aid
What the strongest studies found

The essence, in one line each.

  1. In 40 healthy adults averaging 56 years, six months of an astragaloside-containing astragalus extract was associated with longer median and short telomere length (p = 0.01 and p = 0.004) and a smaller share of telomeres under 3 kbp, with no change on placebo; telomere length is a cellular marker, not a health outcome, and the product was a multi-component extract.Randomised trial. de Jaeger et al., 2024 (Nutrients). PMID 39275278
  2. The review discusses Astragalus membranaceus derived compounds among agents examined for effects on telomere length in vascular ageing, and describes the evidence as mechanistic and preclinical rather than established clinical outcome data.Narrative review. Canale et al., 2025 (Journal of Cardiovascular Development and Disease). PMID 41002620

These are the studies our verdict leans on, chosen from the 35 we read for Astragaloside IV (TA-65 type). The full linked list is below.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.